Indian equities are poised for a constructive phase, with strategists anticipating earnings acceleration and a potential revival in foreign investor interest. While near-term earnings surprises are limited, FY27 is projected to see significant growth. Pharma is favored over IT, with selective opportunities in midcaps and other sectors.
SIP additions at a six-month high amid rising churn
In August, the number of new accounts for systematic investment plans (SIPs) soared to a six-month peak, marking significant activity. Nevertheless, the year-on-year growth showcased